Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases

Joon Seong Park, Dong Hwan Kim, Chul Won Choi, Seong Hyun Jeong, Jin Hyuk Choi, Kihyun Kim, Seok Jin Kim, Chul Won Jung, Deok Hwan Yang, Jun Ho Jang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: This observational study was conducted to document the efficacy and safety of the use of micafungin (Mycamine) as an empirical antifungal agent in febrile neutropenic patients. Methods: Micafungin was administered for sustained fever (>38.4°C) on days 3-5 following the initiation of empirical antibiotic therapy. The overall success rate and side effects were evaluated. Results: A total of 47 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and lymphoma were enrolled in the study. The overall success rate of micafungin was 61.7% (29/47). A total of 3 patients (6.4%) experienced grade 3/4 elevations in their aspartate aminotransferase levels, and 10 patients (21%) experienced grade 3/4 hyperbilirubinemia, 9 of which resolved. Four patients died of septic shock. Younger patients (<50 years) and patients with acute lymphoblastic leukemia exhibited a better response to micafungin than other patients. Patients that were less profoundly neutropenic (≥0.05 × 109/l) also had a better response to micafungin, as did the patients who recovered from their fever or neutropenia. Conclusion: Micafungin has an excellent efficacy (61.7%) and safety profile when used as an empirical antifungal agent in febrile neutropenic patients with hematological disorders.

Original languageEnglish
Pages (from-to)92-97
Number of pages6
JournalActa Haematologica
Volume124
Issue number2
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

Hematologic Diseases
Antifungal Agents
Fever
Safety
Precursor Cell Lymphoblastic Leukemia-Lymphoma
micafungin
Hyperbilirubinemia
Myelodysplastic Syndromes
Septic Shock
Aspartate Aminotransferases
Neutropenia
Acute Myeloid Leukemia
Observational Studies
Lymphoma
Anti-Bacterial Agents

Keywords

  • Hematological diseases
  • Micafungin
  • Neutropenic fever

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. / Park, Joon Seong; Kim, Dong Hwan; Choi, Chul Won; Jeong, Seong Hyun; Choi, Jin Hyuk; Kim, Kihyun; Kim, Seok Jin; Jung, Chul Won; Yang, Deok Hwan; Jang, Jun Ho.

In: Acta Haematologica, Vol. 124, No. 2, 01.10.2010, p. 92-97.

Research output: Contribution to journalArticle

Park, JS, Kim, DH, Choi, CW, Jeong, SH, Choi, JH, Kim, K, Kim, SJ, Jung, CW, Yang, DH & Jang, JH 2010, 'Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases', Acta Haematologica, vol. 124, no. 2, pp. 92-97. https://doi.org/10.1159/000315558
Park, Joon Seong ; Kim, Dong Hwan ; Choi, Chul Won ; Jeong, Seong Hyun ; Choi, Jin Hyuk ; Kim, Kihyun ; Kim, Seok Jin ; Jung, Chul Won ; Yang, Deok Hwan ; Jang, Jun Ho. / Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. In: Acta Haematologica. 2010 ; Vol. 124, No. 2. pp. 92-97.
@article{5c060d4850d94fee86efb57a0521d394,
title = "Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases",
abstract = "Background: This observational study was conducted to document the efficacy and safety of the use of micafungin (Mycamine) as an empirical antifungal agent in febrile neutropenic patients. Methods: Micafungin was administered for sustained fever (>38.4°C) on days 3-5 following the initiation of empirical antibiotic therapy. The overall success rate and side effects were evaluated. Results: A total of 47 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and lymphoma were enrolled in the study. The overall success rate of micafungin was 61.7{\%} (29/47). A total of 3 patients (6.4{\%}) experienced grade 3/4 elevations in their aspartate aminotransferase levels, and 10 patients (21{\%}) experienced grade 3/4 hyperbilirubinemia, 9 of which resolved. Four patients died of septic shock. Younger patients (<50 years) and patients with acute lymphoblastic leukemia exhibited a better response to micafungin than other patients. Patients that were less profoundly neutropenic (≥0.05 × 109/l) also had a better response to micafungin, as did the patients who recovered from their fever or neutropenia. Conclusion: Micafungin has an excellent efficacy (61.7{\%}) and safety profile when used as an empirical antifungal agent in febrile neutropenic patients with hematological disorders.",
keywords = "Hematological diseases, Micafungin, Neutropenic fever",
author = "Park, {Joon Seong} and Kim, {Dong Hwan} and Choi, {Chul Won} and Jeong, {Seong Hyun} and Choi, {Jin Hyuk} and Kihyun Kim and Kim, {Seok Jin} and Jung, {Chul Won} and Yang, {Deok Hwan} and Jang, {Jun Ho}",
year = "2010",
month = "10",
day = "1",
doi = "10.1159/000315558",
language = "English",
volume = "124",
pages = "92--97",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases

AU - Park, Joon Seong

AU - Kim, Dong Hwan

AU - Choi, Chul Won

AU - Jeong, Seong Hyun

AU - Choi, Jin Hyuk

AU - Kim, Kihyun

AU - Kim, Seok Jin

AU - Jung, Chul Won

AU - Yang, Deok Hwan

AU - Jang, Jun Ho

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background: This observational study was conducted to document the efficacy and safety of the use of micafungin (Mycamine) as an empirical antifungal agent in febrile neutropenic patients. Methods: Micafungin was administered for sustained fever (>38.4°C) on days 3-5 following the initiation of empirical antibiotic therapy. The overall success rate and side effects were evaluated. Results: A total of 47 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and lymphoma were enrolled in the study. The overall success rate of micafungin was 61.7% (29/47). A total of 3 patients (6.4%) experienced grade 3/4 elevations in their aspartate aminotransferase levels, and 10 patients (21%) experienced grade 3/4 hyperbilirubinemia, 9 of which resolved. Four patients died of septic shock. Younger patients (<50 years) and patients with acute lymphoblastic leukemia exhibited a better response to micafungin than other patients. Patients that were less profoundly neutropenic (≥0.05 × 109/l) also had a better response to micafungin, as did the patients who recovered from their fever or neutropenia. Conclusion: Micafungin has an excellent efficacy (61.7%) and safety profile when used as an empirical antifungal agent in febrile neutropenic patients with hematological disorders.

AB - Background: This observational study was conducted to document the efficacy and safety of the use of micafungin (Mycamine) as an empirical antifungal agent in febrile neutropenic patients. Methods: Micafungin was administered for sustained fever (>38.4°C) on days 3-5 following the initiation of empirical antibiotic therapy. The overall success rate and side effects were evaluated. Results: A total of 47 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and lymphoma were enrolled in the study. The overall success rate of micafungin was 61.7% (29/47). A total of 3 patients (6.4%) experienced grade 3/4 elevations in their aspartate aminotransferase levels, and 10 patients (21%) experienced grade 3/4 hyperbilirubinemia, 9 of which resolved. Four patients died of septic shock. Younger patients (<50 years) and patients with acute lymphoblastic leukemia exhibited a better response to micafungin than other patients. Patients that were less profoundly neutropenic (≥0.05 × 109/l) also had a better response to micafungin, as did the patients who recovered from their fever or neutropenia. Conclusion: Micafungin has an excellent efficacy (61.7%) and safety profile when used as an empirical antifungal agent in febrile neutropenic patients with hematological disorders.

KW - Hematological diseases

KW - Micafungin

KW - Neutropenic fever

UR - http://www.scopus.com/inward/record.url?scp=77954680894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954680894&partnerID=8YFLogxK

U2 - 10.1159/000315558

DO - 10.1159/000315558

M3 - Article

C2 - 20664196

AN - SCOPUS:77954680894

VL - 124

SP - 92

EP - 97

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 2

ER -